z-logo
Premium
Admissions for antibiotic‐resistant infections in cancer patients during first year of cancer diagnosis: a cross‐sectional study
Author(s) -
SlavovaAzmanova Neli,
Haddow Livia,
Hohnen Harry,
Coombs Geoffrey,
Robinson James O.,
Ives Angela
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13609
Subject(s) - medicine , cancer , genitourinary system , colorectal cancer , chemotherapy , antibiotics , population , surgery , environmental health , microbiology and biotechnology , biology
In this study, linked Western Australian health data were used to determine presence of an antibiotic‐resistant infection ( ABRI ) for all people diagnosed with a primary invasive cancer in 2009. Of 10 858 cancer cases, 154 (1.42%) had an ABRI . Patients with an ABRI were older (71.5 vs 66 years), and more had died in the year following diagnosis (37.7 vs 20.2%, P  < 0.001). The ABRI cohort had a higher proportion of colorectal, genitourinary and haematological cancers (19.5 vs 11.9%; 14.3 vs 9.7% and 16.9 vs 5.8%, respectively). Hospital admissions with an ABRI were longer (22.3 vs 2.9 days, P  < 0.001) and had a higher proportion of unplanned admissions (60.3 vs 15.2%), admissions through emergency department (36.8 vs 8.3%) and intensive care admissions (14.9 vs 1.7%, P  < 0.001). Patients with solid tumours who developed an ABRI were more likely to have received chemotherapy (35.9 vs 27.8%, P  = 0.04). In haematological cancer patients, a greater proportion of the admissions with an ABRI occurred after radiation therapy or chemotherapy ( P  = 0.01 and P  = 0.005, respectively). This study is the first to report population‐level data on ABRI in cancer patients. Patients with an ABRI had more hospital admissions and poorer outcomes.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here